Molecular docking analysis of breast cancer target RAC1B with ligands

Area of Science:

• Oncology
• Computational Chemistry
• Medicinal Chemistry

Background:

• Breast cancer is a significant health concern, necessitating the development of effective chemotherapy preventive strategies.
• Identifying potent inhibitors of key proteins like Rac1b is crucial for novel drug development.
• Rac1b protein is implicated in breast cancer progression, making it a potential therapeutic target.

Purpose of the Study:

• To identify novel inhibitors for the Rac1b protein using structure-based drug design.
• To evaluate the drug-likeness and medicinal chemistry of potential inhibitors.
• To assess the stability and efficacy of identified compounds as potential breast cancer therapeutics.

Main Methods:

• Structure-based drug design was employed to screen available drugs against the Rac1b protein.
• Molecular docking simulations were performed to identify and rank potential inhibitors.
• ADMET studies and molecular dynamics simulations (RMSD, RMSF) were conducted to assess drug likeness and complex stability.

Main Results:

• Several novel inhibitors targeting Rac1b were identified through molecular docking.
• The evaluated therapeutic compounds demonstrated superior stability compared to existing compounds like EHop-016.
• The study identified promising medication possibilities for breast cancer targeting Rac1b.

Conclusions:

• Targeting Rac1b protein with novel inhibitors is a viable strategy for breast cancer treatment.
• The identified compounds show potential as stable and effective therapeutic agents.
• Further research into these compounds could lead to new drug alternatives for breast cancer.